PDF(1508 KB)
Screening of UBE2S interacting protein and construction of prognostic model in hepatocellular carcinoma
Xiaoyan WANG,Hao ZHANG,Zehao GUO,Jun CAO,Zhijing MO
PDF(1508 KB)
PDF(1508 KB)
Screening of UBE2S interacting protein and construction of prognostic model in hepatocellular carcinoma
Objective To screen the interacting protein of ubiquitin-conjugating enzyme E2S (UBE2S) and construct the hepatocellular carcinoma (HCC) based on UBE2S interacting protein prognosis model (UIPM),and to discuss the value of UIPM in assessing the prognosis of the HCC patients. Methods Co-immunoprecipitation (Co-IP) was used to screen the protein complexes binding to Flag-UBE2S. After validation by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting methods;liquid chromatography-mass spectrometer (LC-MS) was used to identify the UBE2S interacting proteins; Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis were conducted on these proteins; the prognosis-related proteins from The Cancer Genome Atlas (TCGA) were cross-referenced with UBE2S interacting proteins by survival package of R software;the key proteins were extracted through LASSO regression analysis to build the UIPM; the prognostic model risk scoring formula was established. The HCC patients in TCGA were divided into high risk group and low risk group based on median value of the risk scores. The predictive accuracy of UIPM was evaluated by receiver operating characteristic curve (ROC), and the predictive accuracy was further validated by International Cancer Genome Consortium (ICGC) Database; univariate regression analysis and multivariate Cox regression analysis were used to detect whether the UIPM risk score was an independent prognostic factor for HCC. Furthermore, the nomogram model was built. Results A total of 97 UBE2S interacting proteins were identified through Co-IP combined with LC-MS analysis.The GO functional enrichment analysis and KEGG signaling pathway enrichment analysis results showed that the interacting proteins were closely associated with cysteine-type endopeptidase activity, oxidative stress, and cell death. The TCGA revealed 5 163 HCC prognosis-related proteins; after intersecting with UBE2S interacting proteins, 40 prognosis-related interacting proteins were found. Seven key proteins were determined through LASSO regression analysis, including UBE2S, heat shock protein family A member 8 (HSPA8), heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1),chaperonin containing TCP1 subunit 3 (CCT3),eukaryotic translation initiation factor 2 subunit 1 (EIF2S1), receptor for activated C kinase 1 (RACK1), and actin related protein 2/3 complex subunit 4 (ARPC4), and the UIPM was constructed. There was significant difference in survival rate of the patients between high risk group and low risk group (P<0.05). The ROC curve analysis results showed the area under ROC curve(AUC) values of UIPM for predicting 1-year, 2-year, and 3-year survival risk scores of the HCC patients were all greater than 0.7, indicating the model had high predictive accuracy. This was also confirmed by ICGC Database data. The univariate and multivariate Cox regression analysis results showed that the UIPM risk score was an independent prognostic risk factor for the HCC patients (P<0.05). The nomogram results showed good consistency between predicted survival rate and actual survival rate of the patient. Conclusion A total of 97 interacting proteins that interact with UBE2S may promote the occurence and devolopment of HCC through oxidative stress and dysregulation of ferroptosis pathways. The UIPM risk score is an independent risk factor for the prognosis of HCC and can be used to predict the outcomes of the patients. UBE2S, HSPA8, HNRNPH1, CCT3, EIF2S1, RACK1, and ARPC4 could be regarded as the new biomarkers and therapeutic targets for HCC.
Ubiquitin-conjugating enzyme E2S / Hepatocellular carcinoma / Co-immunoprecipitation / Liquid chromatograph mass spectrometer / Prognostic analysis
R735.7
| 1 | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. |
| 2 | CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791. |
| 3 | KIRKIN V, DIKIC I. Ubiquitin networks in cancer[J]. Curr Opin Genet Dev, 2011, 21(1): 21-28. |
| 4 | LI Z Y, WANG Y, LI Y D, et al. Ube2s stabilizes β-Catenin through K11-linked polyubiquitination to promote mesendoderm specification and colorectal cancer development[J]. Cell Death Dis, 2018, 9(5): 456. |
| 5 | TANG H, FANG T, JI M, et al. UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1[J]. Biochem Biophys Res Commun, 2021, 578: 7-14. |
| 6 | HU L, CHENG X B, BINDER Z, et al. Molecular and clinical characterization of UBE2S in glioma as a biomarker for poor prognosis and resistance to chemo-radiotherapy[J]. Front Oncol, 2021, 11: 640910. |
| 7 | ZHANG M J, LIU Y, YIN Y, et al. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis[J]. Mol Med, 2022, 28(1): 62. |
| 8 | HU W J, LI M, CHEN Y G, et al. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway[J]. J Ovarian Res, 2021, 14(1): 121. |
| 9 | LIN T H, HSU W H, TSAI P H, et al. Dietary flavonoids, luteolin and quercetin, inhibit invasion of cervical cancer by reduction of UBE2S through epithelial-mesenchymal transition signaling[J]. Food Funct, 2017, 8(4): 1558-1568. |
| 10 | LIU Z, XU L J. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells[J]. BMB Rep, 2018, 51(12): 642-647. |
| 11 | HO J Y, LU H Y, CHENG H H, et al. UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells[J]. Cell Oncol (Dordr), 2021, 44(6): 1325-1338. |
| 12 | QIN Y N, DU J, FAN C F. Ube2S regulates Wnt/β-catenin signaling and promotes the progression of non-small cell lung cancer[J].Int J Med Sci,2020,17(2): 274-279. |
| 13 | GUO Y J, CHEN X Y, ZHANG XW, et al. UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb [J]. Front Oncol, 2023, 13: 992233. |
| 14 | PENG S M, CHEN X, HUANG C Y, et al. UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer[J]. Int J Biol Sci, 2022, 18(8): 3528-3543. |
| 15 | PAN Y H, YANG M, LIU L P, et al. UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2018, 503(2): 895-902. |
| 16 | ZHANG R Y, LIU Z K, WEI D, et al. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development[J]. Signal Transduct Target Ther, 2021, 6(1): 64. |
| 17 | GUI L, ZHANG S C, XU Y Z, et al. UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma[J]. Cell Death Discov, 2021, 7(1): 357. |
| 18 | MA Y L, LI K Z, LI S J, et al. Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma[J]. Int J Biol Macromol, 2018, 119: 225-231. |
| 19 | GOEMAN J J. L1 penalized estimation in the Cox proportional hazards model[J]. Biom J, 2010, 52(1): 70-84. |
| 20 | COMBS J A, DENICOLA G M. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival[J]. Cancers,2019,11(5): 678. |
| 21 | ANGELI J P F, SCHNEIDER M, PRONETH B,et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J].Nat Cell Biol,2014, 16(12): 1180-1191. |
| 22 | YANG W S, SRIRAMARATNAM R, WELSCH M E,et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1/2): 317-331. |
| 23 | JIANG X J, STOCKWELL B R, CONRAD M. Ferroptosis: mechanisms, biology and role in disease[J].Nat Rev Mol Cell Biol,2021,22(4):266-282. |
| 24 | MATSCHKE V, THEISS C, MATSCHKE J. Oxidative stress: the lowest common denominator of multiple diseases[J]. Neural Regen Res, 2019, 14(2): 238-241. |
| 25 | WANG J, CHEN W, WEI W W, et al. Oncogene TUBA1C promotes migration and proliferation in hepatocellular carcinoma and predicts a poor prognosis[J]. Oncotarget, 2017, 8(56): 96215-96224. |
| 26 | JIANG K Q, DONG C Y, YIN Z L, et al. Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis[J]. Cell Death Dis, 2020, 11(11): 972. |
| 27 | XU H, DONG X Y, CHEN Y M, et al. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma[J]. Clin Chem Lab Med, 2018, 56(3): 479-484. |
| 28 | CHEN Y H, PENG C H, CHEN J R, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019, 18(1): 127. |
| 29 | YANG C X, SHAO Y D, WANG X J, et al. The effect of the histone chaperones HSPA8 and DEK on tumor immunity in hepatocellular carcinoma[J]. Int J Mol Sci, 2023, 24(3): 2653. |
| 30 | DUAN F F, WU H, JIA D W, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis[J]. J Hepatol, 2018, 68(6): 1191-1202. |
| 31 | HUANG S L, DONG C R, LI D, et al. ARPC2: a pan-cancer prognostic and immunological biomarker that promotes hepatocellular carcinoma cell proliferation and invasion[J]. Front Cell Dev Biol, 2022, 10: 896080. |
/
| 〈 |
|
〉 |